This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Galtier-Dereure, F Articles by Bringer, J Search for Related Content PubMed PubMed Citation Articles by Galtier-Dereure, F Articles by Bringer, J Social Bookmarking                         What's this?

Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies?

Endocrinology Department

C Biron

Laboratory of Hematology

M Vies

Endocrinology Department

V Bourgeois

Medical Information Department, University Hospital, Montpellier, France

J-F Schved

Laboratory of Hematology

J Bringer

Endocrinology Department

Vascular complications are the main cause of morbidity in diabetes mellitus. However, the risk factors for vascular disease remain uncompletely elucidated. It has been previously suggested that factors other than glycemia may contribute to the development of vasculopathy. In this study we determined the prevalence of phospholipid-binding antibodies in uncomplicated and complicated diabetes.

We studied 53 uncomplicated diabetic patients, with type 1 (n=32) or type 2 (n=21) diabetes; 23 diabetic patients with proliferative retinopathy; 28 diabetic patients with an overt nephropathy; 37 diabetic patients with macroangiopathy and 22 non diabetic control patients. Both lupus anticoagulant and anticardiolipin antibodies were determined.Other risk factors for macroangiopathy were analysed.

The prevalence of phospholipid-binding antibodies was similar in uncomplicated diabetic patients and in controls (type 1 diabetes: 9.4%; type 2 diabetes: 9.5%; control group: 4.6%; P=0.76). In complicated diabetes, the frequency of these antibodies was increased only in patients with overt nephropathy (32.1%, P=0.01) or with macroangiopathy (32.4%, P=0.01) while patients with isolated retinopathy were comparable with uncomplicated diabetic patients (4.3%, P=0.66).Uncomplicated diabetes was not associated with phospholipid-binding antibodies. We found a higher prevalence of these antibodies in diabetic patients with macroangiopathy or nephropathy. These results suggest a potential role of phospholipid-binding antibodies in the progression of vascular complications in diabetes mellitus.

Key Words: lupus anticoagulant • anticardiolipin antibodies • diabetes mellitus • vascular complications

Lupus, Vol. 7, No. 7, 469-474 (1998)
DOI: 10.1191/096120398678920488


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. M. Calvo-Romero and E. M. Lima-Rodriguez Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus Clin. Med. Res., September 1, 2009; 7(3): 93 - 95. [Abstract] [Full Text] [PDF]

				A. J. Trujillo-Santos Diabetic Muscle Infarction: An underdiagnosed complication of long-standing diabetes Diabetes Care, January 1, 2003; 26(1): 211 - 215. [Abstract] [Full Text] [PDF]

				S. MANZI, M. C. M WASKO, and S. MANZI Inflammation-mediated rheumatic diseases and atherosclerosis Ann Rheum Dis, May 1, 2000; 59(5): 321 - 325. [Full Text]

				C. Giusti, R. Schiaffini, D. Bosco, P. Ciampalini, A. Pantaleo, E. M Vingolo, and P. Gargiulo Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy? Br J Ophthalmol, May 1, 2000; 84(5): 531 - 533. [Abstract] [Full Text]

				S. Manzi Systemic lupus erythematosus: a model for atherogenesis? Rheumatology, April 1, 2000; 39(4): 353 - 359. [Full Text] [PDF]